business

Dyne Therapeutics (DYN) Concludes Phase 1/2 ACHIEVE Trial Enrollment

Yahoo Finance · Jun 11, 2026, 10:20 AM · Also reported by 2 other sources

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com Jazz Pharmaceuticals’ Zepzelca fails phase 3 lung cancer trial Investing.com Piper Sandler raises Tenax Therapeutics price target on trial data

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Dyne Therapeutics (DYN) Concludes Phase 1/2 ACHIEVE Trial Enrollment

Also covered by

More in business